Application of panaxadiol saponin instead of dexamethasone to inhibition of RM-1 cell strain rat prostatic carcinoma transplantation tumor in combination with cis-platinum
By replacing dexamethasone with cisplatin in the ginseng glycol group, the toxic side effects of the chemotherapy drug cisplatin and glucocorticoids were solved, and effective inhibition of prostate cancer and improved patient survival rate was achieved.
Patent Information
- Application Number
- CN202411257465.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing chemotherapy drug cisplatin has serious toxic side effects when treating prostate cancer, especially when used in combination with glucocorticoids, which leads to serious side effects and affects the patient's survival.
Ginseng glycol group saponin was used instead of dexamethasone and cisplatin to inhibit the growth of prostate cancer transplant tumors in RM-1 cell line, reduce the toxic side effects caused by hormones, and enhance anti-cancer ability.
Effectively inhibit tumor growth, reduce toxic side effects, improve the body's anti-cancer ability, and significantly improve the patient's survival rate and quality of life.
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of prostate cancer transplant tumor inhibition, and specifically to the use of ginsenosides of the panaxadiol group replacing dexamethasone in combination with cisplatin for inhibiting prostate cancer transplant tumors of RM-1 cell line mice. Background Art
[0002] Prostate cancer mostly occurs in elderly men. Since the implementation of prostate-specific antigen (PSA) group screening in the United States, the detection rate of clinical prostate cancer has increased significantly [1]. The Prostate Disease Prevention and Treatment Research Center of Jilin University was the first in China to carry out prostate cancer group screening. Statistical results show that the average number of prostate cancer cases from 1999 to 2001 increased by 417 times compared with 1986 to 1989 [2]. Chemotherapy is an important aspect of prostate cancer treatment. Cisplatin is widely used in clinical practice due to its low price. However, cisplatin has serious side effects. Its toxic effects are mainly manifested in the following aspects: gastrointestinal symptoms, including diarrhea, nausea, vomiting, etc.; blood system symptoms, including neutropenia, thrombocytopenia, etc.; infection; neurological symptoms, including acute cerebellar syndrome, hearing loss or loss, peripheral nervous system symptoms, etc.; urinary system toxicity; acute respiratory distress syndrome, etc. The main cause of death is severe toxic and side effects caused by improper treatment, among which the most notable is the very serious side effects caused by the use of glucocorticoids during treatment. Summary of the invention
[0003] In view of the deficiencies of the prior art, the present invention provides a method for using ginsenosides of the panaxadiol group to replace dexamethasone in combination with cisplatin for inhibiting RM-1 cell line mouse prostate cancer transplanted tumors, thereby solving the above-mentioned problems.
[0004] To achieve the above objectives, the present invention is implemented through the following technical scheme: Panaxadiol saponins replace dexamethasone combined with cisplatin for the inhibition of RM-1 cell line mouse prostate cancer transplanted tumors, and panaxadiol saponins can replace dexamethasone combined with cisplatin to inhibit tumors.
[0005] Preferably, the experimental method of using panaxadiol saponins to replace dexamethasone in combination with cisplatin to inhibit tumors comprises the following steps: Step 1. Experimental animals, cell lines, drugs and reagents: 60 male C57 mice, weighing 18-20 g; Step 2: Establishment of animal model: discard the culture medium of RM-1 prostate cancer cells that have been cultured and basically covered the wall of the bottle, rinse the culture bottle twice with PBS, add 0.125% trypsin to digest, suck the digested cells into a centrifuge tube, centrifuge at 950r / min for 5 minutes, discard the supernatant, add IMBM culture medium without calf serum, mix with a pipette, take an appropriate amount of cells for counting, centrifuge again, discard the supernatant, and subcutaneously inoculate 1×106 cells per mouse. Observe the success rate of tumor transplantation; Step 3, experimental grouping, 60 C57 mice subcutaneously implanted with tumors were randomly divided into 6 groups 7 days after inoculation, 10 mice in each group; the first model group, 100ul of normal saline; the second cisplatin group 2mg / kg; the third dexamethasone group 2.0mg / kg; the fourth PDS group 2mg / kg; the fifth cisplatin + PDS group 2mg / kg + 2mg / kg; the sixth cisplatin + dexamethasone group 2mg / kg + 2.0mg / kg, the above groups were intraperitoneally injected every day for 14 days, and the general conditions of the animals were observed and recorded; Step 4: Observation indicators and methods: observation of the general condition of the animals; observation of the survival rate of the animals; measurement of tumor volume: use a vernier caliper to measure the long and short diameters of the subcutaneous transplanted tumor, and calculate the tumor volume V according to the general formula [V (mm3) = L × W2 × 0.52], twice a week; Step 5, lymphocyte transformation experiment, under the sterile environment of the clean bench, the spleen was taken out, placed in a plate containing Hank's solution, cut into pieces and repeatedly ground into a single cell suspension, centrifuged at 950 rpm for 10 minutes, the supernatant was discarded and washed twice, and the cells were counted. The cell pellet was adjusted to a concentration of 1×107ml with IMDM culture medium and added to a 96-well plate, 100ul per well, and the stimulator ConA was added according to the experimental design. Three parallel wells were set for each sample and a control well was set. Only IMDM was added, and the total volume of each well was 200ul. Then the culture plate was placed in a 5% CO2 incubator at 37°C and cultured for 20 and 44 hours. The culture plate was taken out, 100ul of the culture medium was discarded from each well, 10ul of 5mg / ml MTT was added to each well, and the culture was continued for 4 hours. The culture plate was taken out, 100ul of DMSO was added, and A570 was measured with an ELISA instrument after 30min to count the lymphocyte transformation rate; Step 6: Statistical analysis: The quantitative data were expressed as x±s, and SPSS Windows for 11 software was used for one-way analysis of variance, and multiple comparisons between sample means were performed.
[0006] Preferably, 24 hours after the last administration in step 3, blood is collected from the mouse eyeballs to kill the animals, and the weights of the heart, liver, spleen, lung, kidney and tumor are weighed, and their coefficients are calculated.
[0007] Preferably, in step 4, the tumor inhibition rate is calculated, tumor inhibition rate %=[1-(average tumor weight of experimental group / average tumor weight of control group)]×100%, and the organ coefficient is calculated, organ coefficient %=organ weight / body weight×100%.
[0008] The present invention provides a method for using ginsenosides of the panaxadiol group to replace dexamethasone in combination with cisplatin for inhibiting RM-1 cell line mouse prostate cancer transplanted tumors. It has the following beneficial effects: ginsenosides are the main active ingredients in ginseng, and ginsenoside PDS is a natural active ingredient extracted from ginseng. In addition to having anti-tumor activity against a variety of tumors, it can also improve the body's resistance. Therefore, the purpose of this experiment is to use ginsenosides to replace dexamethasone in combination with cisplatin to enhance the anti-cancer ability and reduce the serious toxic side effects caused by hormones. DETAILED DESCRIPTION
[0009] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0010] The present invention provides a technical solution: the saponins of the ginsenoside group replace dexamethasone in combination with cisplatin for the inhibition of RM-1 cell line mouse prostate cancer transplanted tumors, and the saponins of the ginsenoside group can replace dexamethasone in combination with cisplatin to inhibit tumors.
[0011] Preferably, the experimental method of using panaxadiol saponins to replace dexamethasone in combination with cisplatin to inhibit tumors comprises the following steps: Step 1. Experimental animals, cell lines, drugs and reagents: 60 male C57 mice, weighing 18-20 g; Step 2: Establishment of animal model: discard the culture medium of RM-1 prostate cancer cells that have been cultured and basically covered the wall of the bottle, rinse the culture bottle twice with PBS, add 0.125% trypsin to digest, suck the digested cells into a centrifuge tube, centrifuge at 950r / min for 5 minutes, discard the supernatant, add IMBM culture medium without calf serum, mix with a pipette, take an appropriate amount of cells for counting, centrifuge again, discard the supernatant, and subcutaneously inoculate 1×106 cells per mouse. Observe the success rate of tumor transplantation; Step 3, experimental grouping, 60 C57 mice all had tumors at the subcutaneous transplantation site, and were randomly divided into 6 groups 7 days after inoculation, with 10 mice in each group; the first model group, 100ul of normal saline; the second cisplatin group 2mg / kg; the third dexamethasone group 2.0mg / kg; the fourth PDS group 2mg / kg; the fifth cisplatin + PDS group 2mg / kg + 2mg / kg; the sixth cisplatin + dexamethasone group 2mg / kg + 2.0mg / kg, the above groups were intraperitoneally injected with the drug every day for 14 days, and the general condition of the animals was observed and recorded; 24h after the last dose, the mice were bled by eye and the animals were killed, and the weights of the heart, liver, spleen, lung, kidney and tumor were weighed, and their coefficients were calculated.
[0012] Step 4. Observation indicators and methods: observation of the general condition of animals; observation of animal survival rate; measurement of tumor volume: use a vernier caliper to measure the major and minor diameters of the subcutaneous transplanted tumor, and calculate the tumor volume V according to the general formula [V(mm3)=L×W2×0.52], twice a week; calculate the tumor inhibition rate, tumor inhibition rate %=[1-(average tumor weight of the experimental group / average tumor weight of the control group)]×100%, calculate the organ coefficient, organ coefficient %=organ weight / body weight×100%.
[0013] Step 5, lymphocyte transformation experiment, under the sterile environment of the clean bench, the spleen was taken out, placed in a plate containing Hank's solution, cut into pieces and repeatedly ground into a single cell suspension, centrifuged at 950 rpm for 10 minutes, the supernatant was discarded and washed twice, and the cells were counted. The cell pellet was adjusted to a concentration of 1×107ml with IMDM culture medium and added to a 96-well plate, 100ul per well, and the stimulator ConA was added according to the experimental design. Three parallel wells were set for each sample and a control well was set. Only IMDM was added, and the total volume of each well was 200ul. Then the culture plate was placed in a 5% CO2 incubator at 37°C and cultured for 20 and 44 hours. The culture plate was taken out, 100ul of the culture medium was discarded from each well, 10ul of 5mg / ml MTT was added to each well, and the culture was continued for 4 hours. The culture plate was taken out, 100ul of DMSO was added, and A570 was measured with an ELISA instrument after 30min to count the lymphocyte transformation rate; Step 6: Statistical analysis: The quantitative data were expressed as x±s, and SPSS Windows for 11 software was used for one-way analysis of variance, and multiple comparisons between sample means were performed.
[0014] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions. The sentence "includes an element defined by ... does not exclude the existence of other identical elements in the process, method, article or device including the element".
[0015] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. The use of ginsenosides from the panaxadiol group to replace dexamethasone and combine with cisplatin for the inhibition of RM-1 cell line mouse prostate cancer transplanted tumors, characterized in that: Panaxadiol saponins can replace dexamethasone combined with cisplatin to inhibit tumors.
2. The use of the ginsenosides of the ginsenosides group according to claim 1 to replace dexamethasone and combine with cisplatin for inhibiting RM-1 cell line mouse prostate cancer transplanted tumors, characterized in that: The experimental method that panaxadiol saponins can replace dexamethasone combined with cisplatin to inhibit tumors includes the following steps: Step 1. Experimental animals, cell lines, drugs and reagents: 60 male C57 mice, weighing 18-20 g; Step 2: Establishment of animal model: discard the culture medium of RM-1 prostate cancer cells that have been cultured and basically covered the wall of the bottle, rinse the culture bottle twice with PBS, add 0.125% trypsin to digest, suck the digested cells into a centrifuge tube, centrifuge at 950r / min for 5 minutes, discard the supernatant, add IMBM culture medium without calf serum, mix with a pipette, take an appropriate amount of cells for counting, centrifuge again, discard the supernatant, and subcutaneously inoculate 1×106 cells per mouse. Observe the success rate of tumor transplantation; Step 3, experimental grouping, 60 C57 mice subcutaneously implanted with tumors were randomly divided into 6 groups 7 days after inoculation, 10 mice in each group; the first model group, 100ul of normal saline; the second cisplatin group 2mg / kg; the third dexamethasone group 2.0mg / kg; the fourth PDS group 2mg / kg; the fifth cisplatin + PDS group 2mg / kg + 2mg / kg; the sixth cisplatin + dexamethasone group 2mg / kg + 2.0mg / kg, the above groups were intraperitoneally injected every day for 14 days, and the general conditions of the animals were observed and recorded; Step 4: Observation indicators and methods: observation of the general condition of the animals; observation of the survival rate of the animals; measurement of tumor volume: use a vernier caliper to measure the long and short diameters of the subcutaneous transplanted tumor, and calculate the tumor volume V according to the general formula [V (mm3) = L × W2 × 0.52], twice a week; Step 5, lymphocyte transformation experiment, under the sterile environment of the clean bench, the spleen was taken out, placed in a plate containing Hank's solution, cut into pieces and repeatedly ground into a single cell suspension, centrifuged at 950 rpm for 10 minutes, the supernatant was discarded and washed twice, and the cells were counted. The cell pellet was adjusted to a concentration of 1×107ml with IMDM culture medium and added to a 96-well plate, 100ul per well, and the stimulator ConA was added according to the experimental design. Three parallel wells were set for each sample and a control well was set. Only IMDM was added, and the total volume of each well was 200ul. Then the culture plate was placed in a 5% CO2 incubator at 37°C and cultured for 20 and 44 hours. The culture plate was taken out, 100ul of the culture medium was discarded from each well, 10ul of 5mg / ml MTT was added to each well, and the culture was continued for 4 hours. The culture plate was taken out, 100ul of DMSO was added, and A570 was measured with an ELISA instrument after 30min to count the lymphocyte transformation rate; Step 6: Statistical analysis: The quantitative data were expressed as x±s, and SPSS Windows for 11 software was used for one-way analysis of variance, and multiple comparisons between sample means were performed.
3. The use of the ginsenosides of the ginsenosides group according to claim 2 as a substitute for dexamethasone in combination with cisplatin for inhibiting RM-1 cell line mouse prostate cancer transplanted tumors, characterized in that: 24 hours after the last administration in step 3, blood was collected from the mouse eyeballs and the animals were killed. The weights of the heart, liver, spleen, lung, kidney and tumor were weighed, and their coefficients were calculated.
4. The use of the ginsenosides of the ginsenosides group according to claim 2 as a substitute for dexamethasone in combination with cisplatin for inhibiting RM-1 cell line mouse prostate cancer transplanted tumors, characterized in that: In the step 4, the tumor inhibition rate is calculated, tumor inhibition rate %=[1-(average tumor weight of the experimental group / average tumor weight of the control group)]×100%, and the organ coefficient is calculated, organ coefficient %=organ weight / body weight×100%.
Citation Information
Patent Citations
Application of panaxadiol saponin in preparing medicines combined with glucocorticoid receptor
CN102008493A
